Inclusion criteria*
To be eligible for enrolment in the study, all the following criteria must be met:
- 18-75 years of age
- Diagnosed (or recognisable symptoms consistent with a diagnosis) with moderate to severe HS for at least one year
- HS lesions (Hurley Stage II-III) present in at least 2 distinct anatomic areas
- Inadequate response to at least 28-days of oral antibiotic treatment for HS (unless oral antibiotic treatments are inadvisable due to important side effects or safety risks)
- Body Mass Index ≥17.5 kg/m2 and body weight ≥40 kg
Selected exclusion criteria*
Participants are excluded from the study if any of the following criteria apply:
- Evidence of other active skin condition that would interfere with the evaluation of HS
- Any condition possibly affecting oral drug absorption
- Current, or within past year, history of severe, progressive or uncontrolled renal,
hepatic, haematological, GI or metabolic, endocrine, pulmonary, cardiovascular
or neurological disease - History of any lymphoproliferative disorder
- History of recurrent (≥2) venous thrombosis or any arterial thromboembolism or known
blood clotting disorder - Malignancies or history of malignancies†
* Full inclusion/exclusion criteria and further study details are available on request.
† Certain malignancies permitted and further study details are available on request.
